Thyrocare Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹271 Cr +24.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
TT

Thyrocare Technologies Ltd

Q1 FY26Healthcare Services

Thyrocare Technologies Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹193Cr
+22.9% YoY
+3.2% QoQ
Net profit
₹38Cr
+58.3% YoY
+72.7% QoQ
Margin
30%
+3 pp YoY
0 pp QoQ
Price₹566
Market cap₹9.5K Cr
P/E52.8

The short version

Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum. Thyrocare expects to maintain EBITDA margins around 30%, with any excess reinvested into the business to drive growth.

From Thyrocare Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum.
  • Expectation to add 1,200 to 1,500 new franchises during the year, maintaining approximately 100 franchise additions per month.
  • Growth driven by both organic expansion (21% in Q1) and inorganic growth via acquisitions (around 2%).
  • Strong focus on increasing franchisee revenue, which grew 20% YoY in Q1 FY26.
  • Partnership revenue grew 36% YoY in Q1, with ongoing expansion in health check segments and onboarding new clients.
  • Expansion of franchise footprint pan-India, with secular growth spread across regions, avoiding concentration in any single geography.

2 more points from Thyrocare Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Investment of approximately ₹3 to ₹4 lakh is required to set up a franchise collection center, including infrastructure like boards, mirrors, and sample collection area.
  • Franchise deposit is minimal and mostly provided by about 10% of franchisees with boards; the deposit is refunded as wallet balance used for business.
  • Thyrocare is moving towards a CAPEX model for equipment procurement in pathology labs, capitalizing machines on their books instead of reagent rental (RR) model.
  • Recent acquisitions (Polo Lab, Vimta Clinical Diagnostics, Think Health) are fully integrated, supporting strategic expansion in North and South India.

2 more points from Thyrocare Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Thyrocare Technologies Ltd Q1 FY26 results — key figures

Thyrocare Technologies Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue193157+22.9%187+3.2%
Operating profit (EBITDA)5842+38.1%57+1.8%
Operating margin30%27%+3 pp30%0 pp
Profit before tax5034+47.1%47+6.4%
Net profit (PAT)3824+58.3%22+72.7%
EPS (₹)2.451.52+61.2%1.36+80.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aster DM Quality (Q1 FY26)

    Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…

  • Dr Agarwal's Hea (Q1 FY26)

    70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…

  • Syngene International (Q1 FY26)

    Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…

  • Yatharth Hospital & Trauma Care Services (Q1 FY26)

    International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q1 FY26 results?

Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum. Thyrocare expects to maintain EBITDA margins around 30%, with any excess reinvested into the business to drive growth.

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

Investment of approximately ₹3 to ₹4 lakh is required to set up a franchise collection center, including infrastructure like boards, mirrors, and sample collection area.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.